**Acknowledgement**: None.

**Funding**: This work was supported by a research grant from Teva Neuroscience, who also provided a Medical Accuracy review of this manuscript.

**Conflict of Interests**: R. Bakshi has received consulting fees from AbbVie, Alkermes, Biogen, Novartis, and Questcor, and has received research support from Biogen, EMD‐Serono, Novartis, Sanofi‐Genzyme, and Teva. The other authors have nothing to disclose.

Introduction {#jon12378-sec-0060}
============

Spinal cord atrophy is present in multiple sclerosis (MS) early in the disease course and is a major contributor to physical disability.[1](#jon12378-bib-0001){ref-type="ref"}, [2](#jon12378-bib-0002){ref-type="ref"}, [3](#jon12378-bib-0003){ref-type="ref"}, [4](#jon12378-bib-0004){ref-type="ref"} Improvements in magnetic resonance imaging (MRI) technology, both in scan acquisition and segmentation techniques, have led to a growing interest in the measurement of spinal cord atrophy to assess disease progression and treatment effects.[1](#jon12378-bib-0001){ref-type="ref"}, [4](#jon12378-bib-0004){ref-type="ref"}, [5](#jon12378-bib-0005){ref-type="ref"}, [6](#jon12378-bib-0006){ref-type="ref"}, [7](#jon12378-bib-0007){ref-type="ref"}, [8](#jon12378-bib-0008){ref-type="ref"} However, few studies to date have assessed the effects of MS disease‐modifying therapy (DMT) on spinal cord atrophy.[1](#jon12378-bib-0001){ref-type="ref"}, [9](#jon12378-bib-0009){ref-type="ref"}, [10](#jon12378-bib-0010){ref-type="ref"}, [11](#jon12378-bib-0011){ref-type="ref"}, [12](#jon12378-bib-0012){ref-type="ref"} Yet, there is increasing evidence to suggest that brain and spinal cord MS involvement are independent from each other[1](#jon12378-bib-0001){ref-type="ref"}, [13](#jon12378-bib-0013){ref-type="ref"}, [14](#jon12378-bib-0014){ref-type="ref"}, [15](#jon12378-bib-0015){ref-type="ref"}, [16](#jon12378-bib-0016){ref-type="ref"} and provide complementary information about disease severity and treatment effects.[17](#jon12378-bib-0017){ref-type="ref"}

Glatiramer acetate (GA), given subcutaneously, is an approved DMT for MS that has been shown to reduce relapse rates, decrease cerebral MRI‐defined lesion load and activity, and limit increases in physical disability.[18](#jon12378-bib-0018){ref-type="ref"} While a few MS studies have demonstrated a reduction in brain atrophy in patients receiving GA,[19](#jon12378-bib-0019){ref-type="ref"}, [20](#jon12378-bib-0020){ref-type="ref"}, [21](#jon12378-bib-0021){ref-type="ref"}, [22](#jon12378-bib-0022){ref-type="ref"} its effect on spinal cord atrophy has not been studied. Our study explored the one‐year effect of GA treatment on cervical spinal cord volume.

Methods {#jon12378-sec-0070}
=======

Subjects {#jon12378-sec-0080}
--------

Our hospital\'s institutional review board approved this study. Participants gave written informed consent. The participant\'s medical record was examined, followed by a telephone interview to determine suitability to enter the study. We excluded those with a history of major medical, neurologic, or neuropsychiatric disorders; current or prior history of substance abuse; or any condition that precluded MRI. Subjects were also excluded if they had congenital or acquired spinal canal narrowing on MRI scans to avoid any confounding myelopathic effects on cord volume. All patients with MS had not experienced a relapse or corticosteroid use within the four weeks before study entry and had initiated GA therapy (20 mg/day subcutaneously) within the 10 years before study entry. Total enrollment was 25 subjects: 15 with relapsing‐remitting MS (RRMS) (13 women) and 10 healthy controls (8 women). Recruitment age was (mean ± SD) 43.6 ± 7.4 years for the MS group and 45.1 ± 5.7 years for healthy controls. There was no statistically significant difference in age and sex distribution between the two groups (*P* \> .05, Table [1](#jon12378-tbl-0001){ref-type="table-wrap"}). An MS specialist neurologist performed clinical examinations every six months, and provided routine clinical care during the observation period. At baseline, patients had a disease duration (time since first symptoms) of 7.5 ± 7.2 years; the time on GA was 2.1 ± 3.1 years. Baseline Expanded Disability Status Scale (EDSS) scores and timed 25‐foot walk (T25FW) values are noted in Table [1](#jon12378-tbl-0001){ref-type="table-wrap"}.

###### 

Clinical and MRI Data in Patients with Multiple Sclerosis and Healthy Controls at Baseline and One‐Year Follow‐Up

                                                                                            Patients      Controls
  ----------------------------------------------------------------------------------------- ------------- -------------
  Number of subjects                                                                        15            10
  Age (years)[†](#jon12378-tbl1-note-0002){ref-type="fn"}                                   43.6 ± 7.4    45.1 ± 5.7
  Range                                                                                     27.4 ‐ 55.2   31.9 ‐ 49.4
  Women, *n* (%)[††](#jon12378-tbl1-note-0002){ref-type="fn"}                               13 (87%)      8 (80%)
  Expanded Disability Status Scale score[\*](#jon12378-tbl1-note-0003){ref-type="fn"}                     
  Baseline                                                                                  1.4 ± 1.5     --
  Follow‐up                                                                                 1.2 ± 1.7     --
  Timed 25‐foot walk (seconds)[\*\*](#jon12378-tbl1-note-0003){ref-type="fn"}                             
  Baseline                                                                                  4.7 ± 1.1     --
  Follow‐up                                                                                 4.9 ± 1.0     --
  Cervical spinal cord cross‐sectional area (mm^2^)                                                       
  Baseline                                                                                  60.0 ± 9.9    61.3 ± 6.9
  Follow‐up                                                                                 61.6 ± 9.7    64.8 ± 8.6
  Change in cross‐sectional area (mm^2^)[\*\*\*](#jon12378-tbl1-note-0003){ref-type="fn"}   1.6 ± 4.5     3.5 ± 3.9

Note: Data are mean ± SD except as noted.

^†^ *P* = .495; ^††^ *P* = 1.0

^\*^ *P* = .44 (baseline vs. follow‐up); ^\*\*^ *P* = .92 (baseline vs. follow‐up); ^\*\*\*^ *P* = .26.
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MRI Acquisition {#jon12378-sec-0090}
---------------

All subjects underwent cervical spinal cord imaging on the same 3T scanner with a consistent acquisition protocol throughout the study. Spine MRI was performed with an eight‐channel phased array coil at 20‐mT/m maximal gradient strength at baseline and one year later. Spinal axial T2 fast spin‐echo images covered the whole spinal cord and had the following parameters: field‐of‐view (FOV), 24 × 19 cm; matrix size, 256 × 256; section thickness, 3 mm with no gap; repitition time (TR), 6,116.66 ms; echo time (TE), 110.24 ms; echo‐train length, 12; number of signal intensity averages, 2; flip angle, 90°; and voxel size, .937 × .937 × 3 mm.

MRI Analysis {#jon12378-sec-0100}
------------

MRI scans were transferred to our laboratory where analysis was performed using the Jim software package (Version 7.0, Xinapse Systems, Northants, United Kingdom; [www.xinapse.com](http://www.xinapse.com)). Analysis was performed by two experienced observers who were unaware of clinical information. Spinal cord measurements were obtained from the C1--C7 vertebral levels, using a semiautomated pipeline. The cord contour was first determined using a highly reproducible active surface tool.[5](#jon12378-bib-0005){ref-type="ref"} Sagittal reconstructed images were cross‐referenced to the axial images to allow precise identification of vertebral levels. Manual adjustments were applied where necessary to assure accurate cord contours. The final cervical (C1--C7) spinal cord cross‐sectional area was obtained by dividing the total volume by the number of axial slices. This method of normalization is based on our previous work.[23](#jon12378-bib-0023){ref-type="ref"} The mean cross‐sectional area obtained in our laboratory by this T2‐derived technique shows high intrarater and interrater reliability, with coefficients of variation of .66% and .99%, respectively.[24](#jon12378-bib-0024){ref-type="ref"}

In addition, the same trained observers assessed the number of spinal cord lesions in each subject. These data are provided for descriptive purposes only.

Statistical Analysis {#jon12378-sec-0110}
--------------------

On‐study one‐year change in spinal cord area was compared between the MS and NC groups using the exact Wilcoxon rank sum test. In the MS group, on‐study change in EDSS and T25W was tested using the Wilcoxon signed rank test. Between group age was compared with the exact Wilcoxon rank sum test and sex was compared with a Fisher\'s exact test. A *P* \< .05 was considered statistically significant.

Results {#jon12378-sec-0120}
=======

There was no statistically significant difference in the on‐study change in spinal cord area between the MS and control groups over one year. The mean change in spinal cord area was 1.6 ± 4.5 mm^2^ in patients with MS and 3.5 ± 3.9 mm^2^ in the control group (*P* = .26) (Table [1](#jon12378-tbl-0001){ref-type="table-wrap"}, Fig [1](#jon12378-fig-0001){ref-type="fig"}).

![Spinal cord change in both groups over one year. Changes in cervical spinal cord cross‐sectional area (one‐year follow‐up minus baseline) in healthy controls (HC) and patients with multiple sclerosis (MS). Boxplots are presented with diamonds representing means, lines representing medians, areas extending from lower to upper quartiles, and whiskers extending to minima and maxima. The mean change in spinal cord area was 1.6 ± 4.5 mm^2^ with 95% confidence interval (−.9, 4.1) in MS, and 3.5 ± 3.9 mm^2^ with 95% confidence interval (.7, 6.3) in HC (*P* = .26).](JON-27-33-g001){#jon12378-fig-0001}

Regarding disability measures, there was no statistically significant difference in EDSS scores between baseline and one‐year follow‐up in the MS group (1.4 ± 1.5 vs. 1.2 ± 1.7, *P* = .44). Similarly, there were no statistically significant on‐study changes in T25FW (4.7 ± 1.1 vs. 4.9 ± 1.0 seconds, *P* = .92) (Table [1](#jon12378-tbl-0001){ref-type="table-wrap"}).

The number of lesions per patient in the whole spinal cord was .40 ± .82 (range 0--2) at baseline, and .46 ± .82 (range 0--2) at follow‐up (Fig [2](#jon12378-fig-0002){ref-type="fig"}). Most of the MS subjects (73%) were free of lesions at both baseline and follow‐up scans. No spinal cord lesions were detected in the healthy controls at either the baseline or one‐year time point.

![Sample images; MRI‐defined spinal cord lesion versus normal appearing spinal cord. Representative T2‐weighted 3T MRI scans are shown. (A) A hyperintense lesion (arrows) indicating a cervical spinal cord lesion (at the C4 vertebral level) is seen in the axial and sagittal planes of a 50‐year‐old woman with relapsing‐remitting MS (disease duration = 16 years, Expanded Disability Status Scale score = 0, timed 25‐foot walk = 4.6 seconds). (B) 31‐year‐old woman, healthy control, with no lesions (axial image shown from the C4 vertebral level).](JON-27-33-g002){#jon12378-fig-0002}

Discussion {#jon12378-sec-0130}
==========

We report the results of a pilot study investigating the one‐year effect on cervical spinal cord volume of GA treatment in patients with RRMS. This was a "real‐world" study with no untreated comparison patient group available for comparison. This reflects the widespread usage and availability of numerous DMTs for RRMS. Atrophy was not detected in patients over one year and there was no difference in their spinal cord area change during the year as compared to healthy controls. These findings may represent a protective effect of GA in preventing spinal cord atrophy and neurodegeneration. Although this inference is not definitive because of the lack of a control untreated MS group, our study provides valuable information, as few studies have examined spinal cord atrophy in response to treatment in RRMS.

Previous studies have shown a partial but significant treatment effect on brain atrophy in MS patients treated with GA.[19](#jon12378-bib-0019){ref-type="ref"}, [20](#jon12378-bib-0020){ref-type="ref"}, [21](#jon12378-bib-0021){ref-type="ref"}, [22](#jon12378-bib-0022){ref-type="ref"} Such an effect can be demonstrated fairly consistently in placebo‐controlled phase III studies of a range of DMTs in patients with RRMS.[22](#jon12378-bib-0022){ref-type="ref"} In terms of the potential effect of GA on spinal cord atrophy, Shipova et al[25](#jon12378-bib-0025){ref-type="ref"} have shown significantly less cervical spinal cord atrophy in MS patients treated with GA versus those on interferon beta treatment. In their study, spinal cord atrophy measurement was based on the linear size of spinal cord on sagittal sections at the level of the inferior margin of the C2 vertebral body.

Similarly, in animal studies, GA treatment was associated with an increase in myelinated axons and decreased microglial/macrophage activation and T‐cell infiltration in an experimental allergic encephalomyelitis (EAE) model. Moreover, there were fewer amyloid precursor protein positive axons in the spinal cord of GA‐treated versus untreated EAE mice, suggesting reduced axonal degeneration.[26](#jon12378-bib-0026){ref-type="ref"} Other mechanistic studies have suggested that GA‐reactive Th2 lymphocytes may have anti‐inflammatory, neuroprotective, and bystander suppressive effects.[18](#jon12378-bib-0018){ref-type="ref"} GA treatment is hypothesized to exert its neuroprotective effect, in part, by upregulating brain‐derived neurotrophic factor (BDNF).[27](#jon12378-bib-0027){ref-type="ref"}

A controversy exists regarding the time of appearance of spinal cord atrophy in the disease course of MS. While some studies have shown spinal cord atrophy early in the course of the disease including in patients with their first symptoms of demyelination or early stages of RRMS,[3](#jon12378-bib-0003){ref-type="ref"}, [28](#jon12378-bib-0028){ref-type="ref"}, [29](#jon12378-bib-0029){ref-type="ref"}, [30](#jon12378-bib-0030){ref-type="ref"}, [31](#jon12378-bib-0031){ref-type="ref"} others have not confirmed these findings and contend that spinal cord atrophy does not appear in MS until later stages of RRMS or in the secondary progressive phase of the disease.[1](#jon12378-bib-0001){ref-type="ref"}, [5](#jon12378-bib-0005){ref-type="ref"}, [8](#jon12378-bib-0008){ref-type="ref"}, [23](#jon12378-bib-0023){ref-type="ref"}, [32](#jon12378-bib-0032){ref-type="ref"} Furthermore, the presence of inflammation and edema, particularly in the early stages of MS, may mask spinal cord atrophy. This lack of sensitivity to early spinal cord atrophy in MS may be potentially overcome by focusing on gray matter (instead of whole spinal cord) volume loss.[7](#jon12378-bib-0007){ref-type="ref"} Hence, it is possible that our findings may have been limited by methodological issues. In addition, the patient characteristics of our sample presented a potential sensitivity bias, owing to the mild disability, and lack of spinal cord lesions in many of the patients, despite their advanced age and disease duration.

In terms of our technical approach, we obtained normalized spinal cord areas using a highly reproducible semiautomated segmentation tool. This segmentation approach was applied to 2‐dimensional images given their availability and our prior demonstration that these images were highly reproducible and sensitive to disease‐specific effects in assessing cord volume.[24](#jon12378-bib-0024){ref-type="ref"} Several groups have used high‐resolution 3‐dimensional images[13](#jon12378-bib-0013){ref-type="ref"}, [33](#jon12378-bib-0033){ref-type="ref"}, [34](#jon12378-bib-0034){ref-type="ref"}, [35](#jon12378-bib-0035){ref-type="ref"} and fully automated segmentation pipelines[6](#jon12378-bib-0006){ref-type="ref"}, [8](#jon12378-bib-0008){ref-type="ref"}, [36](#jon12378-bib-0036){ref-type="ref"} to measure spinal cord volume, which we did not employ in this study. Hence, it is possible that our MRI approach, both on the basis of scan acquisition and postprocessing technique, may have lacked the precision to detect ongoing spinal cord atrophy.

Conclusion {#jon12378-sec-0140}
==========

In this pilot study of patients with RRMS, GA therapy was not associated with any significant ongoing spinal cord atrophy over one year. There was also no significant difference in the one‐year rate of spinal cord area change compared to healthy controls. These results paralleled the lack of clinical worsening and may reflect a treatment effect of GA. However, further studies, addressing a range of methodologic issues and patient characteristics, and a larger sample size, are needed to confirm these preliminary findings.
